Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
Not yet recruiting · NCT07862530 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, retinitis pigmentosa 2, skin disorder, skin neoplasm | Not yet recruiting | Phase 2 | 2026-10-07 | NCT07862530 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Replimune, Inc. | 14 |
| Yana Najjar | 6 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |